Finally Merck decides to give Remicaid back to J&J. So I guess they didn't buy the reverse merger with Schering. At least the lawyers are still working!
Merck retains about 3/4 of what S-P had before the merger. Better outcome than most would have expected but not as nifty as thought before November 09.